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Abstract. Aim: Insulin-like growth factor-1 receptor
(IGF1R) is a tyrosine kinase receptor mediating cell growth
and survival of cancer cells. We studied responses to IGF1R
tyrosine kinase inhibitor NVP-AEW541 combined with
conventional systemic drugs in breast cancer cell lines of
different clinical subtype. Materials and Methods:
Sensitivity to NVP-AEW541, single treatment and
combinations with tamoxifen, trastuzumab, doxorubicin or
paclitaxel, was tested in MCF7, SKBR3 and T47D cells.
Cells were assayed for proliferation, cell death, cell cycle
distribution and phosphorylation of proteins downstream of
IGF1R. Results: Treatment of NVP-AEW541 resulted in
reduced proliferation, G-1 cell cycle arrest and reduced
phosphorylation of protein kinase B (AKT) and
extracellular-signal-regulated protein kinase (ERK).
Sensitivity to IGF1R tyrosine kinase inhibition was low in
T47D cells, despite their high IGF1R expression. NVP-
AEW541 combined with trastuzumab had synergistic
cytotoxic effects in T47D cells, and additive effects were
shown in MCF7 and SKBR3 cells. Also, combination with
doxorubicin had antagonistic effects in T47D cells.
Doxorubicin caused up-regulation of phosphorylated ERK
in T47D cells, which was not inhibited by NVP-AEW541.
Conclusion: Antagonistic effects should be anticipated when
IGF1R inhibitors are combined with conventional systemic
drugs in a subset of breast tumors. Development of
functional biomarkers predicting tumor response to tailored
IGF1R therapy is warranted. 
Interaction of insulin-like growth factor 1 with its key receptor
IGF1R gives strong proliferation and survival signals (1, 2).
Ample evidence has implicated dysregulation of IGF1R
signaling in tumor development and progression (3).
Currently, development of drugs targeting the IGF1R as
anticancer treatment is emerging. Antibodies targeting the
IGF1R have been developed and their activity in multiple
tumor types is now being tested in clinical trials (4). For
example, single-agent activity of figitumumab, a humanized
monoclonal antibody directed against IGF1R, has been
successfully tested for treatment of Ewing’s sarcoma (5).
IGF1R functions as a ligand-activated tyrosine kinase receptor.
Upon ligand binding, a conformational change induces
activation of the kinase. Several docking proteins, such as
SRC homology 2 domain-containing (SHC) protein and
insulin receptor substrates (IRS1-4), are subsequently recruited
to the phosphorylation sites in the cytoplasmic domain. Then
the signal is propagated through the phosphatidylinositol-3-
kinase (PI3-Kinase)/AKT and mitogen-activated protein
(MAP) kinase pathways resulting in cell proliferation and
inhibition of apoptosis (6). IGF1R signaling can also induce
differentiation, malignant transformation and regulate cell–cell
adhesion (2). A dynamic downstream signaling network of
different phosphorylation sites of the receptor and cell context
specific recruitment and activation of signaling molecules
regulates these different functions (7-9). Furthermore, IGF1R
can interact with steroid hormones and their receptors, other
peptide growth factor receptors, such as human epidermal
growth factor (HER) family of receptors, and is intimately
connected to the metabolic functions of insulin through a
shared structural homogeneity to the insulin receptor (IR),
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allowing formation of IGF1R/IR hybrid receptors (10-15).
Following successful introduction of small-molecular weight
inhibitors of related receptor tyrosine kinases, such as
erlotinib, gefitinib and lapatinib, for anticancer therapy (16),
tyrosine kinase inhibitors are being developed selectively
targeting IGF1R, among them NVP-AEW541 (17). Specificity
of tyrosine kinase inhibitors of IGF1R versus IRs has been an
issue. Previous studies showed that NVP-AEW541 inhibits
tumor growth in vitro and in vivo in a panel of solid and
hematological tumors, alone and in combination with
chemotherapeutic drugs (17, 18). Studied efficacy of this agent
has been extended to panels of breast cancer cell lines,
however, translation of responses to IGF1R targeted tyrosine
kinase inhibitors in various breast cancer cell lines into
clinically applicable approaches has proven to be difficult (19-
22). The mainstay of systemic adjuvant and non-adjuvant
treatment for breast cancer nowadays includes anthracycline-
and taxane-based chemotherapy, hormonal therapy with
tamoxifen and/or aromatase inhibitors for hormone receptor-
positive tumors, and targeted therapy, mostly with the HER2
antibody trastuzumab, in HER2-positive tumors (23). We
studied responses to IGF1R tyrosine kinase inhibitor NVP-
AEW541 in different clinical subtypes of breast cancer cell
lines, expressing contrasting levels of the estrogen receptor,
HER2 and IGF1R, and tested combinations with conventional
systemic drugs. 
Materials and Methods
Cell lines. The human breast carcinoma cell lines MCF-7, SKBR3
and T47D were obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA). MCF7 and T47D are
hormone receptor-positive cell lines. SKBR3 is an HER2-positive,
hormone receptor-negative cell line. MCF-7 and T47D were grown
in Roswell Park Memorial Institute (RPMI)-1640 medium
supplemented with 10% fetal calf serum (FCS), SKBR3 was grown
in Dulbecco’s modified eagle’s medium (DME)-high supplemented
with 10% FCS. The cells were routinely passaged twice a week.
Cells grown in monolayer to 80% confluence were detached by 5
min trypsin treatment (Trypsin 0.025%, 1 mM EDTA) and
resuspended in appropriate dilutions in culture medium. Assays
were performed in culture medium with lower serum concentrations,
1% FCS for MCF-7 and SKBR3, 5% FCS for T47D.
Quantification of IGF1R, HER2 and epidermal growth factor receptor
(EGFR) membrane expression. Cells were seeded in 3 ml culture
medium supplemented with 10% FCS in 6-well plates. At day 1, the
culture medium was replaced by low serum-containing medium (see
above) with or without NVP-AEW541 (0.5-5 μM, stock solution 10
mM in DMSO) (gift from Novartis Pharma AG, Basel, Switzerland)
and incubated for another 24 or 72 hours. Cells were harvested at 70-
80% confluency, resuspended and assayed by fluorescence-activated
cell sorting. Analysis of IGF1R, HER2, and EGFR membrane
expression was performed using a flow cytometer (Epics Elite;
Coulter Electronics, Hialeah, FL, USA; and FACScalibur; Becton
Dickinson Medical Systems, Sharon, MA, USA). For IGF1R,
phycoerytrocin (PE)-conjugated mouse anti-human IGF1Rα (BD
Biosciences Pharmingen, San Jose, CA, USA) was used, and PE-
conjugated mouse IgG1,κ (BD Biosciences Pharmingen) was taken as
an isotype control. For HER2 detection trastuzumab (humanized IgG1
monoclonal antibody against HER2; Genentech, San Francisco, CA,
USA) and for EGFR detection cetuximab (humanized monoclonal
antibody against EGFR; Merck, Darmstadt, Germany) were used as
primary antibodies, followed by incubation with fluorescein
isothiocyanate (FITC)-conjugated anti-human IgG (Fc-specific)
antibody. FITC-conjugated anti-human IgG antibody alone was taken
as an isotype control. Membrane expression was determined by
subtracting the mean fluorescent intensity (MFI) of the isotype control
from the MFI in presence of the detection antibody. Comparisons
were made by paired Student’s t-test.
Cytotoxicity assay. Sensitivity of MCF-7, SKBR3 and T47D to NVP-
AEW541 was tested with 3-(4,5 dimethylthiazol-2yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Prior to the experiments,
the optimal cell density was assessed to ensure exponential growth of
cells at 96 hours in 96-well microculture plates in conditions of low
serum culture used for the experiments. For the experiments, MCF-
7 and T47D cells were seeded at 5,000 cells per well and SKBR3 at
7,500 cells per well into 96-well flat-bottom cell culture plates. NVP-
AEW541 (1-10 μM), as single treatment, or combined with
trastuzumab (1-100 μg/ml), paclitaxel (1-4 nM), or doxorubicin (5-
50 nM), was added after attachment of the cells to the culture plate.
Tamoxifen (0.5-2 μM) was combined with NVP-AEW541 for MCF-
7 and T47D cells and cetuximab (0.5-50 μg/ml) was combined with
NVP-AEW541 for T47D and SKBR3 cells. Furthermore, cells were
treated with IGF1 (1-500 ng/ml; Abcam, Cambridge, UK) and IGF1R
neutralizing (mouse monoclonal) antibody αIR-3 (0.125-1.0 μg/ml,
Abcam). In cases of combined treatment, both drugs were added
simultaneously and cells were exposed continuously to the drugs. All
experiments were performed in quadruplicates and confirmed in at
least three independent experiments. The percentage of cell survival
was calculated by dividing the mean of the treated samples by the
mean of the untreated sample, after subtraction of background
extinction. The concentration of NVP-AEW541 single treatment
yielding 50% inhibition (IC50 values) were calculated. Treatment
effects of combined treatments were calculated as follows:
Enhancement ratio (ER)=(Survival(modulator+NVP-AEW541)/
Survival(modulator)×100)/Survival (NVP-AEW541). Outcomes of
ER≤0.8 were considered synergistic, ER≥1.2 antagonistic, and
intermediary values, additive effects (24). 
Trypan blue cell counts and analysis of apoptosis. In parallel, cells
were seeded and treated as described for caspase activity assay and
trypan blue cell counts (0.5 ml total volume, 24-well plates). At the
designated time points, cell numbers and viability of harvested cells,
resuspended in the collected supernatant, were assessed by trypan
blue exclusion. This experiment was performed in duplicate and
every sample was counted twice. Results are expressed relative to
the number of initially seeded cells. Activity of caspase-3 and -7
after exposure to NVP-AEW541 for 24 and 72 hours was
determined using the fluorescence peptide substrate Ac-DEVD-AFC
(Sigma-Aldrich, Zwijndrecht, the Netherlands), according to the
manufacturer’s instructions. Relative caspase-3/-7 activity was
expressed as the ratio of that of treated to untreated cells. Staining
with acridine orange was used as well to distinguish apoptotic cells
from vital cells in SKBR3 and T47D cells. 
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Cell cycle analysis. Exponentially growing cells were harvested and
washed in phosphate buffered saline (PBS), and then fixed and
permeabilized by ice-cold ethanol. Cells were stored at 4˚C for up to
48 hours. Prior to the addition of propidium iodide (PI), the cells
were washed and incubated with RNAse for 15 min at room
temperature. After PI incubation, the DNA content of at least 5,000
cells was measured by flow cytometry and analyzed using ModFit
LT software (Verity Software House, Topsham, ME, USA).
Differences in cell cycle distribution between treated and untreated
samples were analyzed by Chi-square test. 
Western blot analysis. To determine phosphorylation status of the
IGF1R and downstream proteins AKT and ERK, cells were cultured
in 6-well plates to a confluence of 70% in culture media
supplemented with 10% FCS. Cells were then serum starved for 8
hours and treated with IGF1R inhibitor NVP-AEW-514 (2.5 μM)
and the antibody αIR-3 (1 μg/ml) for 10 min and 6 hours. Five
minutes before harvesting, the cells were stimulated with 100 ng/ml
IGF1. Combination effects of doxorubicin and NVP-AEW541 were
determined by adding NVP-AEW541 at 2.5 μM 8 hours before or 8
hours after treatment with doxorubicin at 0.5 μM in culture media
containing 1 and 5% FCS, respectively. Cells were harvested on ice,
washed three times in ice-cold PBS and cell lysates were prepared
with lysis buffer consisting of mammalian protein extraction reagent
(M-PER) with 1:100 Protease Inhibitor Cocktail and 1:100
Phosphatase Inhibitor (Pierce, Rockford, IL, USA). After
determination of protein concentrations by Bradford analysis, cell
lysates clarified of insoluble components were dissolved in sodium
dodecyl sulfate (SDS)-sample buffer with 10% 2-β-mercaptoethanol
to a final concentration of 1 μg/μL protein and boiled for 5 min. The
samples were stored at –20˚C until analysis. Equivalent amounts of
cell lysate were separated by 10% SDS-polyacrylamide gel
electrophoresis (1 hour 180 V; BioRad, Veenendaal, the Netherlands)
and transferred to a polyvinylidene difluoride (PVDF) membrane (1
hour 250 mA; Immobilon-P; Millipore, Billerica, MA, USA). After
appropriate washing and blocking of the membrane (TBS-tween-
milk; Sigma Aldrich), focus proteins were detected by the respective
antibody directed towards phospho p44/42 MAPK (ERK)
(thr202/204) E10 (mouse monoclonal, 1:2000 in TBS-t-milk),
phospho AKT (ser473) (rabbit; 1:1000 in BSA), AKT (rabbit, 1:1000
in BSA), phosphorylated IGF1R (tyr1135/1136)/IR (tyr1150/1151)
(monoclonal rabbit, 1:1000 in BSA) (all: Cell Signaling, Danvers,
MA, USA) and ERK-1 (k-23):sc-94 (polyclonal rabbit, 1:800 in
BSA; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and with
overnight incubation at 4˚C with 1:1000 chlorohexidine. A secondary
horseradish peroxidase (HRP)-conjugated antibody directed to mouse
(rabbit-anti-mouse) or rabbit (goat-anti-rabbit) (1:1500 in TBS-t-
milk; DakoCytomation, Glostrup, Denmark) was used and staining
was performed with Lumilight Plus (western blotting substrate;
Roche, Almere, the Netherlands) or for actin staining BM
chemiluminescence blotting substrate (POD; Roche).
Results
Sensitivity to IGF1R tyrosine kinase inhibition was tested in
three breast cancer cell lines with different membrane
expression levels of IGF1R, HER2 and EGFR. MCF7 and
T47D are hormone receptor positive cell lines, expressing high
levels of IGF1R. Whereas MCF7 expresses very low levels of
HER2 and EGFR, T47D expresses intermediate levels of
HER2 and EGFR; SKBR3 is an HER2-positive, hormone
receptor-negative cell line, expressing low levels of IGF1R and
high levels of EGFR (Figure 1). IGF1 stimulation enhanced
proliferation in MCF7 (60% at 100 ng/ml), but not in SKBR3
and T47D. NVP-AEW541 reduced proliferation as measured
by MTT assays in all tested cell lines in a dose-dependent
manner (IC50 MCF7=2.9±0.6 μM, SKBR3=4.9±0.4 μM,
T47D=5.6±0.4 μM) (Figure 2). This was confirmed by trypan
blue cell counts; however, no significant effect on caspase
activity as an indicator of apoptosis was shown. By acridine
orange staining, small numbers of apoptotic cells were found:
12% in SKBR3 cells treated with 5 μM NVP-AEW541. Cell
cycle distribution changed significantly on treatment with
NVP-AEW541 with reduction of the S-phase fraction and
increase of the G-0/G-1 fraction (Figure 3A). IGF1R
membrane expression levels were significantly reduced by
20% after 24-hour treatment with 2.5 μM NVP-AEW541 in
all cell lines. After 72-hour treatment, however, persistent
receptor down-regulation was only seen in T47D cells (Figure
4). The neutralizing anti-IGF1R antibody αIR-3 did not have
any substantial effect on cell survival of any of the cell lines. 
NVP-AEW541 combined treatment. NVP-AEW541 combined
with trastuzumab had synergistic cytotoxic effects in T47D
cells (ER=0.78±0.07, at doses of 5 μM and 100 μg/ml,
respectively). This combination also synergistically reduced
the S-phase fraction (Figure 3B). Additive effects were shown
in SKBR3 and MCF7 cells. NVP-AEW541 combined with
doxorubicin had antagonistic effects in T47D cells
(ER=1.75±0.26, at doses of 6 μM and 25 nM, respectively),
irrespective of treatment sequence (Figure 5). Additive effects
for NVP-AEW541 and doxorubicin were shown in SKBR3
and MCF7 cells. All other combinations tested revealed
additive effects. On protein level (Figure 6), phosphorylated
IGF1R/IR level was not measurable in SKBR3 and T47D
cells (below detection limit), but was evident in MCF-7 cells
after IGF1 stimulation. We found AKT phosphorylation was
up-regulated by IGF1 stimulation both in MCF-7 and T47D
cells, as well as complete down-regulation of IGF1 induced
phosphorylated AKT in both cell lines in response to NVP-
AEW541 and αIR-3 after longer incubation times. In SKBR3
cells AKT was constitutively activated and not further up-
regulated by IGF1 stimulation, yet in response to NVP-
AEW541, AKT was down-regulated. The ERK antibody
detects pERK1 at p44 and, to a lesser extent, pERK2 at p42.
In MCF7 cells both phosphorylated variants of ERK are up-
regulated in response to IGF1, and this up-regulation is only
partially blocked by NVP-AEW541. In T47D and SKBR3
cells, an amount of constitutively active ERK2 exists. Upon
IGF1 stimulation, strong up-regulation of phosphorylation of
both variants of ERK occurs in T47D and only slightly in
SKBR3 cells. In addition, in T47D cells NVP-AEW541 more
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profoundly blocked IGF1 induced ERK activation than in
SKBR3 cells. Constitutive levels of pERK were not blocked.
IGF1 induced ERK activation was blocked by NVP-AEW541
more effectively in T47D compared to MCF7 cells (Figure
6). Doxorubicin caused a slight up-regulation of
phosphorylated ERK in T47D cells and NVP-AEW541 did
not inhibit this up-regulation. No significant effect of single
treatment with doxorubicin or combined with NVP-AEW541
on phosphorylated AKT levels were seen (Figure 7). Adding
doxorubicin resulted in an enormous increase of cells arrested
in G-2/M and S phases, to a degree in which proper fitting
became inaccurate. Adding NVP-AEW541 resulted in a slight
increase of cells in the G-0/G-1 phase compared to single
treatment with doxorubicin (Figure 3C). 
Discussion 
The aim of this work was to show tumor responses to NVP-
AEW541 in breast carcinoma cell lines of different clinical
subtypes and test the combination with conventional
systemic drugs. Selection of our cell lines was based on the
histologic parameters which direct current selection of breast
cancer therapy. The SKBR3 cell line represents HER2-
overexpressing breast tumors. MCF7 and T47D represent
luminal hormone receptor-positive breast cancer. Because
MCF7 is strongly ER positive and HER2 negative, it may
represent luminal A breast cancer, whereas T47D might
represent luminal B breast cancer, because this cell line is
ER positive and weakly HER2 positive. No cell line
ANTICANCER RESEARCH 32: 1309-1318 (2012)
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Figure 2. Sensitivity to NVP-AEW541 as measured by 3-(4,5
dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay,
mean±SEM (n=4).
Figure 1. Membrane expression levels of insulin-like growth factor-1 receptor (IGF1R), human epidermal growth factor receptor 2 (HER2) and
epidermal growth factor receptor (EGFR) in breast cancer cell lines MCF7, SKBR3 and T47D (mean fluorescent intensity (MFI)).
representing the triple negative or basal-like subtype was
included in the present study. Best responses to IGF1R-
directed therapy are anticipated in high IGF1R-expressing
cells. However, the magnitude of effect of NVP-AEW541 in
our experiments was not proportional to IGF1R membrane
expression. T47D cells, although expressing high levels of
IGF1R, showed resistance to IGF1R-targeted drugs in
comparison to high IGF1R-expressing MCF7 cells, and was
even less sensitive to NVP-AEW541 than low IGF1R-
expressing SKBR3 cells. These data may indicate that
luminal B type tumors may be resistant to IGF1R-targeted
therapy in contrast to the luminal A type, irrespective of
IGF1R expression. NVP-AEW541 induces G-0/G-1 arrest in
breast cancer cell lines grown in monolayer and inhibits
proliferation, while apoptosis is not a prominent effect.
Comparison of previous studies suggests more dramatic
effects of IGF1R inhibition in anchorage-independent growth
conditions (anoikis) compared to monolayer (proliferation)
(25). Our results in monolayer culture are consistent with the
results of others by IGF1R inhibition with αIR-3 (26). We
further show IGF1R down-regulation by NVP-AEW541.
IGF1R antibodies are known to cause receptor down-
regulation by internalization and degradation of the receptor
by endocytosis (27-29). Mechanisms by which receptor
down-regulation occurs with tyrosine kinase inhibition of the
receptor are as yet unclear. Receptor down-regulation may
contribute to the effects of therapeutic drugs on IGF1R
functioning, or may be merely a manifestation of a low
proliferative state. Our assays may indicate the latter, as we
saw a similar effect on receptor down-regulation occurring
at a later timepoint in untreated cells. Cells might well have
been beyond their exponential growth phase at this later
timepoint. AKT and ERK are both critical components of
two respective major downstream proliferation and survival
pathways of IGF1R. In the presence of IRS1, IGF1R
signaling through phosphorylation of receptor
phosphorylation sites induces recruitment and
phosphorylation of IRS proteins, resulting in recruitment of
p110, the catalytic subunit of PI3K, generation of
phosphoinositol trisphosphate, and subsequent activation of
Hartog et al: Conventional Therapies Combined with IGF1R Inhibitor for Breast Cancer  
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Figure 3. A: Dose-dependent reduction of S-phase fraction in MCF7
cells after 72 hour treatment with NVP-AEW541 (n=3). *p-value 0.002,
χ
2
-test. B: Synergistic reduction of S-phase fraction by concurrent
treatment of T47D cells with NVP-AEW541 and trastuzumab (100
μg/ml). C: Effect on cell cycle distributions of concurrent treatment of
T47D cells with NVP-AEW541 (5 μM) and doxorubicin (25 nM).
AKT. The IRS1/PI3K/AKT pathway is considered a
preferential pathway of IGF1R (30). The second major
survival pathway results from Rat sarcoma (RAS) signaling
after recruitment of adaptor proteins to the activated IGF1R
and subsequent activation of transcriptional programs
downstream of the ERKs, also referred to as the MAPK
pathway. The requirement for activation of AKT or ERK in
IGF1R-mediated (survival) signals appears to be context
dependent and has not yet been fully determined. Moreover,
other receptor tyrosine kinases, such as HER2 and EGFR,
share the same downstream signal transduction (16). Our
breast cancer cell lines of different clinical subtypes
exhibited differential phosphorylation levels of both AKT
and ERK in low serum conditions, upon stimulation with
IGF1, and blocking by NVP-AEW541, respectively. A
previous study comparing MCF7 to T47D cells, expressing
almost identical IGF1R levels, has suggested that reduced
sensitivity/resistance to NVP-AEW541 in T47D cells is
determined by a lack of IGF1R signaling through
downstream proteins IRS1 and PI3K/AKT (22). In contrast
to this report, we found AKT phosphorylation by IGF1
stimulation both in MCF-7 and T47D cells, as well as down-
regulation of phosphorylated AKT in both cell lines in
response to NVP-AEW541. Caution should be exercised
with comparing data of the same putative cancer cell lines
yet cultured in separate laboratories, as these may differ
considerably due to genetic instability and digression.
However, our data seem to confirm that T47D cells do not
depend on the IRS1/PI3K/AKT pathway for survival and
proliferation, whether or not the pathway is functional,
causing resistance to NVP-AEW541. Contrary to
expectations, in SKBR3 cells, levels of constitutively
activated AKT, which did not further change upon IGF1
stimulation, were nonetheless down-regulated in response to
NVP-AEW541. This may suggest constitutively activated
IGF1R, or, more likely, non-IGF1R-specific effects of NVP-
AEW541. Non-IGF1R-specific effects of NVP-AEW541 are
supported by reported dosage-dependent specificity of the
drug. The IC50 of inhibition of IGF1R autophosphorylation
by NVP-AEW541 is much lower (0.086 μM) than the
effective doses in our study (2.9-5.6 μM). The reported IC50
of inhibition of IR autophosphorylation by NVP-AEW541 is
2.3 μM (17). Although we did not exclude co-targeting of
both IGF1R and IR by NVP-AEW541 in our study, the
measured phosphorylated receptor levels by an antibody
directed against both phosphorylated forms of IGF1R and IR
showed no activity in SKBR3 cells. Another possibility may
be that heterodimeric or heterotrimeric complexes of IGF1R
with HER1-4 receptors are formed and co-targeted by NVP-
AEW541 (15, 31). Several lines of evidence suggest
synergistic augmentation of trastuzumab effects by NVP-
AEW541 in HER2-positive breast cancer with or without
acquired trastuzumab resistance (19, 20). IGF1 induced ERK
phosphorylation in MCF7 cells was only partly blocked by
NVP-AEW541, possibly due to remaining activity of non-
tyrosine kinase domains, such as serine clusters. Constitutive
levels of pERK in SKBR3 and T47D cells were not blocked,
suggesting constitutive ERK activation independently of the
IGF1R. Whereas combinations of NVP-AEW541 with
cytostatic agents had additive effects in MCF7 and SKBR3
ANTICANCER RESEARCH 32: 1309-1318 (2012)
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Figure 4. Insulin-like growth factor-1 receptor (GF1R) membrane expression (mean fluorescent intensity (MFI)) after 24-hour and 72-hour treatment
with 2.5 μM NVP-AEW541 (n=4).
cells, comparable to responses seen by other study groups
(32-34), we found an antagonistic effect of the combination
of NVP-AEW541 with doxorubicin in T47D cells. Varying
sequences of NVP-AEW541 and doxorubicin administration
did not alter the antagonistic effects in our hands. Timing of
IGF1R-targeted therapy by antibodies has previously been
shown to affect responses to chemotherapy both in vitro and
in vivo (35). The optimal sequence proved to be doxorubicin
followed by anti-IGF1R antibody. Clearly, these results do
not apply to IGF1R tyrosine kinase inhibition in the same
way. This could be explained by different time-effect curves
of antibodies vs. tyrosine kinase inhibition, for instance
NVP-AEW541 blocked IGF1R activity more quickly than
the antibody αIR-3. No plausible explanation was found for
the antagonistic effect in T47D cells. Up-regulation of
phosphorylated ERK levels after single treatment with
doxorubicin, which NVP-AEW541 did not inhibit, suggests
ERK up-regulation occurs downstream of the IGF1R, and
upstream inhibition may therefore be in vain. On the other
hand, such a mechanism is unlikely to cause contrary effects.
Cell cycle distribution analysis suggests additive effects of
doxorubicin and NVP-AEW541. Consistent with previous
reports, doxorubicin alone arrests cells in the G-2/M phase
by interacting with DNA synthesis and transcription by DNA
intercalation (36). Due to the NVP-AEW541 induced G-0/G-
1 arrest, G-2/M arrest by doxorubicin is reduces, but the
overall S-phase fraction is not altered. The biological
response to IGF1R inhibitors in cancer cells is diverse and
may be dependent on multiple factors, according to the
literature. Many studies have indicated not only IGF1R
expression, but interaction with related receptors, such as
estrogen receptor, HER2 family of receptors and the IR, as
well as functionality of downstream proteins, such as IRS1
and -2, and AKT, on determining functional responses of the
Hartog et al: Conventional Therapies Combined with IGF1R Inhibitor for Breast Cancer  
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Figure 5. Antagonistic effects of doxorubicin (25 nM) and NVP-AEW541 combinations in a 96-h MTT assay of T47D cells.
IGF1R and sensitivity to anti-IGF1R agents. Our study
confirms the results of many other studies and we see
conventional results in a majority of our cell lines and drug
combinations. However, more problematic issues arise when
we look in further detail into the minority of unexplained
contrary effects. Neither in our study, nor in the existing
literature, did we find satisfactory clarifications of
unpredicted responses, which raises the possibility of
unexpected and contrary effects in clinical use. Analogous to
the cell lines MCF7 and T47D, responses to IGF1R
inhibitory drugs may be unpredictable in patients with high
IGF1R-expressing and hormone-responsive breast cancer. It
also may be possible that combining chemotherapy with
IGF1R tyrosine kinase inhibitors may be beneficial in certain
patients in combination with certain chemotherapeutic drugs,
but disadvantageous in others. Tyrosine kinase inhibitors are
ANTICANCER RESEARCH 32: 1309-1318 (2012)
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Figure 7. The effect of doxorubicin and NVP-AEW541 on MCF7 (left), T47D (center) and SKBR3 (right). Lanes: 1: untreated cells; 2: doxorubicin
0.5 μM 24 h; 3: 2.5 μM NVP-AEW541 followed by doxorubicin 0.5 μM 24 h; 4: doxorubicin 0.5 μM 24 h followed by 2.5 μM NVP-AEW541.
Figure 6. The effect of aIR-3 and NVP-AEW541 on phosphorylated IGF1R and downstream AKT and ERK in serum-starved MCF7 (A) T47D (B) and
SKBR3 (C) cells. 1: untreated cells; 2: IGF1 (100 ng/ml) for 5 min; 3: NVP-AEW541 (2.5 μM) for 10 min followed by IGF1 (100 ng/ml) for 5 min;
4: NVP-AEW541 (2.5 μM) for 6 h followed by IGF1 (100 ng/ml) for 5 min; 5: aIR-3 (1 μg/μl) for 10 min followed by IGF1 (100 ng/ml) for 5 min;
6: aIR-3 (1 μg/μl) for 6 h followed by IGF1 (100 ng/ml) for 5 min; Actin was used as a control for loaded protein concentrations.
generally considered less specific compared to monoclonal
antibodies and may be more prone to having upredictable
clinical effects. In order to address such issues, we believe
new techniques and biomarkers are needed to overcome the
shortcomings of the studies to date. 
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